Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Equity (2016 - 2025)

Protalix BioTherapeutics (PLX) has 15 years of Return on Equity data on record, last reported at 0.1% in Q3 2025.

  • For Q3 2025, Return on Equity rose 42.0% year-over-year to 0.1%; the TTM value through Sep 2025 reached 0.1%, up 42.0%, while the annual FY2024 figure was 0.08%, 38.0% down from the prior year.
  • Return on Equity reached 0.1% in Q3 2025 per PLX's latest filing, down from 0.13% in the prior quarter.
  • Across five years, Return on Equity topped out at 4.61% in Q4 2021 and bottomed at 10.44% in Q3 2021.
  • Average Return on Equity over 5 years is 0.06%, with a median of 0.15% recorded in 2023.
  • Peak YoY movement for Return on Equity: crashed -1065bps in 2021, then surged 1074bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 4.61% in 2021, then tumbled by -72bps to 1.3% in 2022, then tumbled by -89bps to 0.15% in 2023, then tumbled by -47bps to 0.08% in 2024, then surged by 35bps to 0.1% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.1% in Q3 2025, 0.13% in Q2 2025, and 0.09% in Q1 2025.